Liliana Candia

Liliana Candia

Auto-generated profile, based on publicly available information

Liliana Candia

Hospital Regional Primero de Octubre ISSTE/Fuerzas Armadas, Mexico City, Mexico

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2022 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
YLYing-Ying Leung
Ying-Ying Leung
TKTatiana V. Korotaeva
Tatiana V. Korotaeva
LCLiliana Candia
Liliana Candia
SPSusanne Juhl Pedersen
Susanne Juhl Pedersen
WBWilson Bautista-Molano
Wilson Bautista-Molano
OFOliver FitzGerald
Oliver FitzGerald
Objective: We aimed to compile evidence for the efficacy and safety of therapeutic options for the peripheral arthritis domain of psoriatic arthritis (PsA) for the revised 2021 Group in Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations.Methods: A working group consisting of clinicians and patient research partners was convened. We reviewed the evidence from new randomized controlled trials (RCTs) for PsA treatment from February 19, 2013, to August 28, 2020. We used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE)-informed approach to derive evidence for the classes of therapeutic options for 3 patient groups: (1) naïve to treatment, (2) inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), and (3) inadequate response to biologic DMARDs (bDMARDs). Recommendations were derived through consensus meetings.Results: The evidence review included 69 RCTs. We derived GRADE evidence for each class of therapeutic options and achieved consensus for the recommendations. For patients naïve to treatment, the working group strongly recommends csDMARDs (methotrexate, sulfasalazine, leflunomide) and phosphodiesterase 4 inhibitors, and emphasizes regular assessment and early escalation to achieve treatment target. bDMARDs (tumor necrosis factor inhibitors [TNFi], interleukin 17 inhibitors [IL-17i], IL-12/23i, IL-23i) and Janus kinase inhibitors (JAKi) are also strongly recommended. For patients with inadequate response to csDMARDs, we strongly recommend TNFi, IL-17i, IL-12/23i, IL-23i, and JAKi. For those who had prior experience with bDMARDs, we strongly recommend a second TNFi, IL-17i, IL-23i, and JAKi. The evidence supporting nonpharmacological interventions was very low. An expert panel conditionally recommends adequate physical activity, smoking cessation, and diet to control weight gain.Conclusion: Evidence supporting optimal therapy for the peripheral arthritis domain of PsA was compiled for the revised 2021 GRAPPA treatment recommendations.

1 April 2011 in The American Journal of the Medical Sciences
Verified
Journal Article
Closed access
RVRafael Valle-Oñate
Rafael Valle-Oñate
LCLiliana Candia
Liliana Candia
CRConsuelo Romero-Sánchez
Consuelo Romero-Sánchez
PSPedro Santos-Moreno
Pedro Santos-Moreno
ERElsa Reyes
Elsa Reyes
JLJohn Londono
John Londono

1 September 2009 in Revista Colombiana de Reumatología
Verified
Journal Article
Closed access
COCarlos D. Ochoa
Carlos D. Ochoa
FRFabián Ramírez
Fabián Ramírez
GQGerardo Quintana
Gerardo Quintana
CTCarlos Toro
Carlos Toro
CCCarlos Alberto Cañas
Carlos Alberto Cañas
AAAntonio Iglesias-Gamarra A
Antonio Iglesias-Gamarra A

16 September 2025 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
FSFernando Sommerfleck
Fernando Sommerfleck
RGRodrigo Garcia-Salinas
Rodrigo Garcia-Salinas
DVDiego Vila
Diego Vila
DPDaniel Palleiro
Daniel Palleiro
DFDaniel G. Fernández-Ávila
Daniel G. Fernández-Ávila
WBWilson Bautista-Molano
Wilson Bautista-Molano